(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/093724 A1

(51) International Patent Classification:
A61P 21/00 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2021/056517

(22) International Filing Date:
25 October 2021 (25.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/105,850	26 October 2020 (26.10.2020)	US
63/106,172	27 October 2020 (27.10.2020)	US
63/200,955	05 April 2021 (05.04.2021)	US
63/201,157	15 April 2021 (15.04.2021)	US
63/202,317	06 June 2021 (06.06.2021)	US
63/202,372	08 June 2021 (08.06.2021)	US
63/202,900	29 June 2021 (29.06.2021)	US
63/260,725	30 August 2021 (30.08.2021)	US
63/261,398	20 September 2021 (20.09.2021)	US

(71) Applicant: **SCHOLAR ROCK, INC.** [US/US]; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **NOMIKOS, George**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **SONG, Guochen**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **IARROBINO, Ryan**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **CHYUNG, Yung**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.**; Finnegan Henderson Farabow Garrett & Dunner LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY

(57) Abstract: The present disclosure relates to therapeutic methods, uses, and compositions comprising an anti-pro/latent myostatin antibody to treat spinal muscular atrophy (SMA) in human subjects, either as monotherapy or as an adjunct to a motor neuron-directed therapies, such as SMN upregulator/corrector therapies.

WO 2022/093724 A1